Multi-Party Data Rights. For clinical protocol(s) where Investigational Agent is used in combination with another investigational agent supplied to NCI pursuant to a CTA or CRADA between NCI and an entity not a Party to this CRADA [hereinafter referred to as “Third Party”], the access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive as follows:
Appears in 7 contracts
Samples: Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Material Transfer Agreement (Newlink Genetics Corp)
Multi-Party Data Rights. For clinical protocol(sProtocol(s) and Non-Clinical Study(ies) where Investigational Agent is used in combination with another investigational agent supplied to NCI pursuant to a CTA or CRADA between NCI and an entity not a Party to this CRADA [(hereinafter referred to as “Third Party”]), the access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive as follows:
Appears in 6 contracts
Samples: Agreement, Health Service, Agreement (Tracon Pharmaceuticals, Inc.)
Multi-Party Data Rights. For clinical protocol(sProtocol(s) and Non-Clinical Study(ies) where Investigational Agent is used in combination with another investigational agent supplied to NCI pursuant to a CTA or CRADA between NCI and an entity not a Party to this CRADA [hereinafter referred to as “Third Party”], the access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive as follows:
Appears in 2 contracts
Samples: Agreement (Tracon Pharmaceuticals, Inc.), Agreement (Tracon Pharmaceuticals Inc)
Multi-Party Data Rights. For clinical protocol(s) where Investigational Agent is used in combination with another investigational agent supplied to NCI pursuant to a CTA or CRADA between NCI and an entity not a Party to this CRADA [‘hereinafter referred to as “Third Party”], the access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive as follows:as
Appears in 2 contracts
Samples: Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)
Multi-Party Data Rights. For clinical protocol(sProtocol(s) where Investigational Formulary Agent is used in combination with another investigational agent supplied to NCI pursuant to a CTA or another Formulary CRADA between NCI and an entity not a Party to this CRADA [or another agreement between the institution that Approved Investigator is associated with and an entity not a Party to this CRADA (hereinafter referred to as “Third Party”]), the access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive and reciprocal as follows:
Appears in 1 contract
Samples: Public Health Service
Multi-Party Data Rights. For clinical protocol(sProtocol(s) where Investigational Formulary Agent is used in combination with another investigational agent supplied to NCI pursuant to a CTA or Formulary CRADA between NCI and an entity not a Party to this CRADA [(hereinafter referred to as “Third Party”]), the access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive as follows:
Appears in 1 contract
Samples: Public Health Service
Multi-Party Data Rights. For clinical protocol(sProtocol(s) or Non-Clinical Study(ies) under the Research Plan where Investigational Agent is used in combination with another investigational agent supplied to NCI pursuant to a CTA or CRADA between NCI and an entity not a Party to this CRADA [(such entity, hereinafter referred to as a “Third Party”], ) the access and use of Multi-Party Data by the Collaborator and the Third Party shall be co-exclusive as follows:
Appears in 1 contract
